Delivering the Next Wave of Innovation to Treat Serious Illness

Moderna is creating first in class in vivo medicines known as messenger RNA Therapeutics™, which enable the body to produce its own healing proteins. This is a quantum change in the way protein therapeutics are produced and used, creating the possibility to treat unmet medical needs that cannot be addressed with current technologies.

Our novel chemistry enables messenger RNA to elude the body’s innate immune response. Once delivered, stable messenger RNA is translated into active, native protein by cells’ natural, well-tuned machinery for protein production. messenger RNA Therapeutics™ enable the in vivo production of both intracellular proteins, which remain within the cells, and secreted proteins, which are released into the bloodstream and act to restore function elsewhere in the body.

Messenger RNA has unique advantages as a platform, as novel drugs may be made and dosed in biolocally relevant ways with unprecedented ease and speed:

  • Native, wild-type proteins are produced and studied in vivo, negating the need for extensive, in vitro biology research.
  • Messenger RNA Therapeutics™ can be developed and tested in just a few weeks, enabling an expedited process from concept to first-in-man studies on the order of less than one year.
  • All messenger RNA Therapeutics™ are made using the same reagents in the same cell-free production process, enabling rapid, cost-effective GMP manufacturing. This is possible given the chemical similarities between all messenger RNAs, which vary only in their RNA sequence.

To date, we have made great strides in advancing messenger RNA as a drug platform, and have screened more than 100 new chemistries. Our current formulation represents a 50-fold increase in in vivo protein expression over our first generation chemistry, even as we have exponentially reduced the cost associated with manufacturing our messenger RNA Therapeutics™.

New Data

Learn about the ability of Moderna’s messenger RNA therapeutics™ to repair and regenerate damaged heart tissue in a study published in Nature Biotechnology.

Read more.